Hansa Biopharma has announced positive topline results from a study investigating Idefirix (imlifidase) in patients who have undergone HLA-incompatible kidney transplantation. 

The biopharmaceutical company announced the primary objective of the post-authorisation efficacy study (PAES) was met, with 90% of highly sensitised kidney transplant patients achieving one‑year graft failure‑free survival – following Idefirix pre‑treatment to convert a positive crossmatch against a deceased donor to negative prior to transplantation.   

In patients treated with Idefirix, at one year, mean estimated glomerular filtration rate (eGFR) was 52.4 mL/min/1.73 m², graft survival was 92%, and patient survival was 98%. 

Results show the study was well conducted, with patient retention greater than 94%. Idefirix was generally well tolerated, with a safety profile consistent with previous clinical trial experience. 

Imlifidase is conditionally approved in the European Union under the brand name Idefirix as a desensitisation treatment for highly sensitised adult patients prior to kidney transplantation from deceased donors. As part of the conditional marketing authorisation, the European Medicines Agency (EMA) requested a post‑authorisation efficacy study (PAES) for Idefirix. 

“These positive results represent a significant milestone for Idefirix and for Hansa,” said Renée Aguiar-Lucander, CEO of Hansa Biopharma. 

“The one‑year graft failure‑free survival observed in this highly sensitised patient population confirms the clinical benefit of Idefirix and demonstrates expected efficacy outcomes supported by a safety profile consistent with prior clinical experience.  

“With this post‑authorisation requirement fulfilled, we look forward to submitting an application for conversion to full marketing authorization to the EMA by the end of 2026.”